| Good but not good enough: Clinical trial participation of patients with myelodysplastic syndromes |
|
Cancer |
Myelodysplastic Syndromes (MDS) |
| Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse |
|
Blood Advances |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Getting personal with myelodysplastic syndromes: is now the right time? |
|
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
| Germline variants in acquired aplastic anemia: current knowledge and future perspectives |
|
Haematologica |
Aplastic Anemia |
| Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT |
|
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
| Germline mutations in MDS/AML predisposition disorders |
|
Current opinion in hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Germline DDX41 mutations define a significant entity within adult MDS/AML patients |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Germline and somatic genetic landscape of pediatric myelodysplastic syndromes |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Genomics of myelodysplastic/myeloproliferative neoplasm |
|
Seminars in Diagnostic Pathology |
Myelodysplastic Syndromes (MDS) |
| Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence |
|
JCO Precision Oncology |
Myelodysplastic Syndromes (MDS) |
